Obermatt
See Similar Stocks →

MBX Biosciences

NSQ:MBX · US55287L1017
PharmaceuticalsSmall

360

30
Medium confidence — indicative
Profit price85
Owner Earnings Yield1
Dividend Yield1
Sales & asset price28
Return on Capital21
Cash Return on Capital25
Return on Equity29
Profit margins—

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth20
Long-Term EPS Growth4
Reinvestment13
Price momentum90
Debt load97
Refinancing58
Debt Payback1
Liquidity17
Analyst ratings46
Opinion Changes50
Price Target Upside82
Market mood7
Value Creation5/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

MBX Biosciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2019
Employees66
Websitembxbio.com
ISINUS55287L1017
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
EndocrinologyObesityBiotechnologyHealth CareWellness

Description

MBX Biosciences, Inc. (MBX), a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Leveraging this expertise, the company des…

Analysis

Middle-of-the-road

MBX Biosciences, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 5/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
38
2026

All-time high

38

Jun 2026

All-time low

30

Mar 2026

Average rank

34

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
—
—
—
—
Price/Earnings
88
—
—
—
Price/Book
28
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
59
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare MBX Biosciences with its peers
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Oramed Pharmaceuticals
NAQ:ORMP
47
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Insmed
NSQ:INSM
51
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
ACADIA Pharmaceuticals
NSQ:ACAD
80
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Lipocine
NAQ:LPCN
39
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →